Compliance with follow-up in patients with testicular cancer receiving adjuvant chemotherapy: A novel study

Author:

Erkan Anil1,Keten Tanju2,Guzel Ozer2,Barali Deniz1,Basboga Serdar2,Kilic Metin1,Caglayan Volkan3,Koc Akif1,Tuncel Altug2

Affiliation:

1. University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital

2. University of Health Sciences, Ankara City Hospital

3. University of Health Sciences, Bursa City Hospital

Abstract

Abstract Purpose The aim of this study was to investigate the compliance with follow-up in patients receiving adjuvant chemotherapy (ACT) for testicular cancer at two academic hospitals. Methods. The study analyzed 104 patients with testicular tumors who had undergone surgery at least a year before and received ACT between March 2017 to March 2022. The mean follow-up was 29.2 ± 16.2 (12–73) months. Patients were classified as fully compliant (100% compliance), moderately compliant (50–99%), poorly compliant (1–49%), and non-compliant (no attendance) according to their compliance with the follow-up schedule. Results At the end of the first year, 76% of patients were fully compliant. By the end of the second year, this number dropped to 50%. Furthermore, 25% of patients were identified as non-compliant in the second year, and only 4.3% in the third year. When comparing patients who were compliant and non-compliant at first and second-year follow-up, no statistically significant difference was found according to age, tumor size, disease stage, or ACT regimen (p = 0.938, p = 0.784, p = 0.867, and p = 0.282, respectively). Conclusion and Implications for Cancer Survivors This study showed that full compliance with follow-up gradually decreased over the years and that the factors examined were not able to predict this decrease. Prospective studies can help to design individualized education and follow-up programs, taking into account the tumor stage of each patient.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3